So that in the study by Liu et al., administration of anti-CD19 CAR-NK cells was not associated with the development of CRS, neurotoxicity, or GVHD, and there was no increase in inflammatory cytokines, including interleukin-6, above baseline [240]. This evidence concerns the gene CD19 and graft versus host disease.